NDATOPICALSOLUTION
Approved
Jul 2023
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
5
Clinical Trials (5)
Long-Term Follow-up Study of Cantharidin (YCANTH [VP-102/TO-208]) in Patients With Common Warts (Verruca Vulgaris)
Started Mar 2026
600 enrolled
Common Warts (Verruca Vulgaris)Common WartsHuman Papilloma Virus (HPV)+1 more
Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2)
Started Dec 2025
300 enrolled
Common WartsCommon Warts (Verruca Vulgaris)Human Papilloma Virus (HPV)+1 more
Effect of Darapladib on Cantharidin-Induced Inflammatory Blisters in Subjects With Type 2 Diabetes Mellitus (T2DM)
Started Feb 2014
9 enrolled
Atherosclerosis
Phase I Methodology Study to Validate the Cantharidin Blister Model in Healthy Volunteers
Started Aug 2010
40 enrolled
Inflammation
Cantharidin-induced Skin Blister for Testing Anti-inflammatory Effects of Macrolides
Started Jun 2009
44 enrolled
Inflammation
Loss of Exclusivity
LOE Date
Feb 19, 2041
182 months away
Patent Expiry
Feb 19, 2041
Exclusivity Expiry
Jul 21, 2028